8-K 1 a4329231.txt INTERLEUKIN GENETICS 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) Of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2003 INTERLEUKIN GENETICS, INC. -------------------------- (Exact name of registrant as specified in its charter) Delaware 000-23413 94-3123681 -------- --------- ---------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification No.) incorporation) 135 Beaver Street, Waltham, MA 02452 ------------------------------------- (Address of principal executive offices) Registrant's telephone number, including area code: (781) 398-0700 -------------- Item 5. Other Events. ------- ------------- On January 30, 2003, Interleukin Genetics, Inc. publicly disseminated a press release announcing the securing of additional interim financing to support operations through February 2003. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto Item 7. Financial Statements and Exhibits. ------- ---------------------------------- (c) Exhibit 99.1 Press Release dated January 30, 2003 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTERLEUKIN GENETICS, INC. -------------------------- (Registrant) Date: January 30, 2003 /s/ Fenel M. Eloi --------------------------------------- Fenel M. Eloi, Chief Operating Officer, Chief Financial Officer, Treasurer and Secretary and Treasurer